Psychedelic Medicine Goes Mainstream
Nico@sweet_nicouze
The idea
I think psychedelic medicine is about to go mainstream, with the first FDA approvals possible within the next year or so. About 40% sits in the drug developers closest to the finish line, where approval news could swing things hard, and I balance that with 25% in the clinics and providers who get paid regardless of which drug wins, plus 23% in larger pharma companies already buying into the space. I keep 12% in cash to ride out the volatility around regulatory decisions. I plan to hold for years and would rethink this if approvals stall or the clinical data turns negative.
What it owns
- These companies own the psychedelic drugs closest to FDA approval, so they gain the most if the first approvals land. · Definium Therapeutics, Inc.Its LSD tablet candidate showed positive results for depression and anxiety, with an FDA approval filing expected soon., Compass Pathways plcIt is the closest competitor to achieve the first psilocybin approval for treatment-resistant depression, with an FDA filing expected soon., Helus Pharma Inc.It is developing a psilocybin-modeled drug through late-stage trials as another potential path to regulatory approval in psychedelic medicine., GH Research PLCIt makes an inhaled form of a fast-acting psychedelic designed for short clinic sessions, potentially more practical than longer treatment formats.40%
- Psychedelic drugs need supervised sessions in clinics, so the providers and distributors get paid no matter which drug wins. · LifeStance Health Group, Inc.It operates a large network of psychiatrists and therapists who would prescribe and supervise psychedelic treatment once drugs are approved., Neuronetics, Inc.It operates clinics treating depression patients with brain stimulation, the exact population that would receive psychedelic therapy if approved., Acadia Healthcare Company, Inc.It runs behavioral health hospitals and treatment centers already equipped for the monitored care that psychedelic sessions require., Universal Health Services, Inc.It is the largest operator of behavioral health hospitals in the US, positioning it to provide supervised psychedelic treatment if approved drugs enter those facilities., Cencora, Inc.It distributes controlled and restricted-access drugs requiring special handling and tracking, the logistics needed for psychedelic medicines regardless of which drug wins approval.25%
- Big drugmakers are buying psychedelic programs, so they profit from the field while spreading the risk across many other drugs. · Johnson & JohnsonIt sells a ketamine-related nasal spray already delivered under clinical supervision, demonstrating that doctors and insurers will pay for supervised drug sessions., Eli Lilly and CompanyIt acquired psychedelic drug candidates through AtaiBeckley, giving one of the world's largest drugmakers resources to advance the programs., AbbVie Inc.It acquired Gilgamesh's lead psychedelic drug, putting a large drugmaker's development and sales capabilities behind the program.23%
- Cash12%